171 related articles for article (PubMed ID: 37666068)
21. Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling.
Zheng Y; Wang N; Wang S; Zhang J; Yang B; Wang Z
J Exp Clin Cancer Res; 2023 May; 42(1):129. PubMed ID: 37210553
[TBL] [Abstract][Full Text] [Related]
22. Endoplasmic reticulum stress mediates the myeloid-derived immune suppression associated with cancer and infectious disease.
Lou X; Gao D; Yang L; Wang Y; Hou Y
J Transl Med; 2023 Jan; 21(1):1. PubMed ID: 36593497
[TBL] [Abstract][Full Text] [Related]
23. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
[TBL] [Abstract][Full Text] [Related]
24. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
[TBL] [Abstract][Full Text] [Related]
25. The Voltage-Gated Hv1 H
Cozzolino M; Gyöngyösi A; Korpos E; Gogolak P; Naseem MU; Kállai J; Lanyi A; Panyi G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047188
[TBL] [Abstract][Full Text] [Related]
26. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients.
Okano S; Abu-Elmagd K; Kish DD; Keslar K; Baldwin WM; Fairchild RL; Fujiki M; Khanna A; Osman M; Costa G; Fung J; Miller C; Kayashima H; Hashimoto K
Am J Transplant; 2018 Oct; 18(10):2544-2558. PubMed ID: 29509288
[TBL] [Abstract][Full Text] [Related]
27. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z; Qin J; Qian Y; Huang C; Liu X; Wang N; Li L; Chao Y; Tan B; Zhang N; Qian M; Li D; Liu M; Du B
J Hematol Oncol; 2024 Feb; 17(1):9. PubMed ID: 38402237
[TBL] [Abstract][Full Text] [Related]
28. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
29. Regulation of DNA-PK activity promotes the progression of TNBC via enhancing the immunosuppressive function of myeloid-derived suppressor cells.
Han J; Wan M; Ma Z; Yi H
Cancer Med; 2023 Mar; 12(5):5939-5952. PubMed ID: 36373232
[TBL] [Abstract][Full Text] [Related]
30. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
31. Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer.
Tcyganov EN; Hanabuchi S; Hashimoto A; Campbell D; Kar G; Slidel TW; Cayatte C; Landry A; Pilataxi F; Hayes S; Dougherty B; Hicks KC; Mulgrew K; Tang CA; Hu CA; Guo W; Grivennikov S; Ali MA; Beltra JC; Wherry EJ; Nefedova Y; Gabrilovich DI
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34228641
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer.
Jianyi D; Haili G; Bo Y; Meiqin Y; Baoyou H; Haoran H; Fang L; Qingliang Z; Lingfei H
Cancer Immunol Immunother; 2023 Jan; 72(1):73-85. PubMed ID: 35725835
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
34. Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sjögren's syndrome.
Wei Y; Peng N; Deng C; Zhao F; Tian J; Tang Y; Yu S; Chen Y; Xue Y; Xiao F; Zhou Y; Li X; Zou H; Rui K; Lin X; Lu L
Cell Mol Immunol; 2022 Dec; 19(12):1361-1372. PubMed ID: 36369368
[TBL] [Abstract][Full Text] [Related]
35. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
36. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
37. Expansion of Polymorphonuclear Myeloid-Derived Suppressor Cells in Patients With Gout.
Zhong L; Li S; Wen Y; Zheng J; Liu F; Cao D; Liu Y
Front Immunol; 2020; 11():567783. PubMed ID: 33154749
[TBL] [Abstract][Full Text] [Related]
38. Decreased Polymorphonuclear Myeloid-Derived Suppressor Cells and ROS Production Correlated Closely with Bronchopulmonary Dysplasia in Preterm Infants.
Liu W; Li S; Li Y; Shen W; Chen H; Li X; Cai L; Wu F; Liu Y; Meng Q; Jiang X
Oxid Med Cell Longev; 2022; 2022():9010354. PubMed ID: 36193058
[TBL] [Abstract][Full Text] [Related]
39. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
40. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
